Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab versus platinum-based doublet as first-line treatment for PD-L1-positive advanced non-small cell lung cancer
NL-OMON47625Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Apr 2016; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47625.